

FORM 39

[RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC

TEST REPORT

ISSUED TO:

Meghalayan Medical Drugs And Services Limited New colony shillong, DHS, laitumkhrah, Office of the mission director, NHM, Shillong, East Khasi Hills Meghalaya, 793003

Shillong - 793003 MFG, LICENCE No:

REPORT NO

ISSUE DATE

23/11/2023

CUSTOMER REFERENCE TRF

DATE

: 17/11/2023

PAGE NO

: 1 of 3

SAMPLE DETAILS

SAMPLE REGISTRATION DETAILS

Sample Name

: Tab Metformin 500mg

Sample Quantity Received Sample Registration Date

100.00 Tablets

Sample Submitted/Drawn by

: 20/11/2023 : Client

Sep-2025

Batch Size Date of Expiry N/A

Sample Receipt Date

Registration No

Name of Manufacturer

N/A

Batch No.

MMDSL QC-0015

Date of Mfg.

: Oct-2023

17/11/2023

SAMPLE ANALYSIS DETAILS

Analysis Starting Date

21/11/2023

Analysis Completion Date

23/11/2023

TEST RESULT										
SL No.	TEST PARAMETER	TESTING / REF. PROCEDURE	LABEL CLAIM	MON	ACCEPTANCE LIMIT	RESULTS				
1	Description	Indian Pharmacopoeia 2022	**		White colour biconvex caplet shaped uncoated tablet having breakline in one side and plain on other side.	White colour biconvex caplet shaped uncoated tablet having breakline in one side and plain on other side.				
2	Identification A	Indian Pharmacopoeia 2022	120	; !	The IR spectrum obtained with the sample should concordant with the reference spectrum of metformin HCL	The IR spectrum obtained with the sampleis concordant with the reference spectrum of metformin HCL				



QA.15-0.0.3

FORM 39

[RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC

TEST REPORT

ISSUED TO:

Meghalayan Medical Drugs And Services Limited New colony shillong, DHS, laitumkhrah, Office of the mission director, NHM, Shillong, East Khasi Hills Meghalaya, 793003

REPORT NO

23/11/2023 ISSUE DATE **CUSTOMER REFERENCE** TRF


DATE : 17/11/2023 PAGE NO : 2 of 3

Shillong - 793003 MFG. LICENCE No:

TEST RESULT

			EST RESULT		1	
SL No.	TEST PARAMETER	TESTING / REF. PROCEDURE	LABEL CLAIM	UOM	ACCEPTANCE LIMIT	RESULTS
3	Identification B	Indian Pharmacopoeia 2022	i i		An orange-red colour should produced which darkens on keeping	An orange-red colour produced which darkens on keeping
4	Identification C	Indian Pharmacopoeia 2022	3	(=-)	A curdy white ppt should formed which should not soluble in HNO3 but soluble in dilute ammonia solution.	A curdy white pptis formed which insoluble in HNO3 but soluble in dilute ammonia solution.
5	Uniformity of weight	Indian Pharmacopoeia 2022	i.f.	%	(±)5.0	Avg wt : 751.67 mg , (-) Dev : 1.03 , (+) Dev : 2.02
6	Disintigration	Indian Pharmacopoeia 2022	3	Min./Sec.	NMT 15 Minutes	Min: 02 Min 25 Sec, Max: 03 Min 12 Sec
7	Dissolution	Indian Pharmacopoeia 2022	500 mg/Tab	% of L.C.	NLT 75.0	Avg: 89.11, Max 90.54, Min: 88.19
8	Assay	Indian Pharmacopoeia 2022	500 mg/Tab	% of L.C.	475.0 - 525.0 mg/Tab i.e. 95.0 - 105.0	486.75 mg/Tab i.e. 97.34
Ģ	Related Substances	Indian Pharmacopoeia 2022		%	Dicyandiamide impurity : NMT 0.02 ,Any other impurities : NMT 0.1	Dicyandiamide impurity :0.0029, Any other impurities : Not detected

In the opinion of the undersigned, the Sample referred to above is of Standard Quality / is not of Standard Quality as defined in the Act or the Rules madethere under for the reasons given below:



QA.15.0.0.3

FORM 39

[RULE 150 - E(F)] APPROVAL NUMBER: T-22/DC

TEST REPORT

ISSUED TO:

Meghalayan Medical Drugs And Services Limited

New colony shillong, DHS, laitumkhrah, Office of the mission director, NHM, Shillong, East Khasi Hills Meghalaya, 793003

Shillong - 793003 MFG. LICENCE No :

REPORT NO

EFRAC/2023/DRG/RG/03656

3 23/11/2023 ISSUE DATE

CUSTOMER REFERENCE TRF DATE

PAGE NO

17/11/2023

: 3 of 3

23/11/2023

UOM

: Unit of Measurement

REMARKS

: The sample is tested as per test procedure shared by client and Opinion on Quality is drawn against the results obtained

for tested parameters only.

Note

-END OF THE TEST REPORT-

